Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis
European Journal of Neurology · 2025
DOI: 10.1111/ene.70264 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Ferdinando Clarelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Raffaele Scientific Institute, Division of Neuroscience, Institute of Experimental Neurology, Laboratory of Human Genetics of Neurological …. Hauptthemen laut MEDLINE: Disease Progression, Multifactorial Inheritance, Multiple Sclerosis, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Despite effective therapeutic control of relapses, many patients with multiple sclerosis (MS) experience, from the earliest phases of disease, disability accrual, which mostly occurs as progression independent of relapse activity (PIRA). In this observational study, we aimed at evaluating the genetic contribution to PIRA, using polygenic risk scores (PRS) in a cohort of 1162 Italian patients.
Methods
PRS were derived from the largest multi‐centric genome‐wide association study on MS severity, conducted on more than 20,000 patients. The scores were computed at 5 p ‐value thresholds after a clumping procedure. Association with the rate of PIRA events was tested by fitting negative binomial regression models.
Results
Analyses revealed a trend for association of PRS with the rate of PIRA events, which were significant in the subset of patients with age at onset ≤ 50 years (Rate Ratio = 1.148, 95% CI: 1.01 to 1.304, p = 0.0328). An interaction effect was identified between PRS and AAO, indicating a significant mild antagonistic effect (RR int = 0.98, 95% CI: 0.96 to 1.0, p = 0.033).
Conclusions
Our results suggest an influence of severity‐related genetic load on the rate of PIRA events, especially in subjects with disease onset before the age of 50 years, characterized by a less prominent effect of aging processes on disability accumulation. This finding supports previous observations from other studies of an age‐dependent influence of genetic risk scores on complex traits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS San Raffaele Scientific Institute, Division of Neuroscience, Institute of Experimental Neurology, Laboratory of Human Genetics of Neurological Disorders, Milan, Italy.
- IRCCS Ospedale San Raffaele, Neurology Unit and MS Center, Milan, Italy.
- Università Vita-Salute San Raffaele, Milan, Italy.
- IRCCS Ospedale San Raffaele, Division of Neuroscience, Institute of Experimental Neurology, Neuroimaging of CNS White Matter Unit, Milan, Italy.
- IRCCS Ospedale San Raffaele, Neurorehabilitation Unit and Neurophysiology Service, Milan, Italy.
ORCID-Profile: Ferdinando Clarelli, Melissa Sorosina, Antonino Giordano, Lucia Moiola, Maria A Rocca, Massimo Filippi, Federica Esposito
Zitieren
APA
Clarelli, F., Sorosina, M., Giordano, A., Mascia, E., Visentin, G., Missaglia, M., Moiola, L., Rocca, M. A., Filippi, M., & Esposito, F. (2025). Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70264
Vancouver
Clarelli F, Sorosina M, Giordano A, Mascia E, Visentin G, Missaglia M, et al. Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis. European Journal of Neurology. 2025. doi:10.1111/ene.70264
BibTeX
@article{Clarelli2025,
author = {Clarelli, Ferdinando and Sorosina, Melissa and Giordano, Antonino and Mascia, Elisabetta and Visentin, Giulia and Missaglia, Matteo and Moiola, Lucia and Rocca, Maria A and Filippi, Massimo and Esposito, Federica},
title = {Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70264}
}
EUVIMED